Analysis of miR-148b expression differences in stage-I and II parosteal osteosarcoma

Lin,Wenjun; Wang,Lu; Yang,Shengwu; Chen,Xin; Zhu,Xiongbai; Chen,Piji

doi:10.3892/ol.2018.8709

Analysis of miR-148b expression differences in stage-I and II parosteal osteosarcoma

Authors:
- Wenjun Lin
- Lu Wang
- Shengwu Yang
- Xin Chen
- Xiongbai Zhu
- Piji Chen
View Affiliations

Affiliations: Department of Orthopedic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, BGI Shenzhen, Shenzhen, Guangdong 518000, P.R. China
Published online on: May 16, 2018 https://doi.org/10.3892/ol.2018.8709
Pages: 998-1002

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of human serum albumin-micro RNA miR-148b in patients with stage-I and II parosteal osteosarcoma and its effect on prognosis were investigated. A total of 47 cases of fresh tissues of stage-I and II parosteal osteosarcoma and the corresponding para-carcinoma normal bone tissues resected by operation were collected; the expression of miR-148b in parosteal osteosarcoma tissues and normal bone tissues was detected, and the correlations of miR-148b expression in parosteal osteosarcoma tissues with clinicopathological parameters and prognosis were analyzed. The expression level of miR-148b in parosteal osteosarcoma tissues was significantly lower than that in para-carcinoma normal tissues (P<0.05). It was found that the low expression of miR-148b was correlated with the lung metastasis (P<0.05). Moreover, Kaplan-Meier survival curve analysis showed that the overall survival rate of patients in the low-expression miR-148b group was lower than that in the high-expression group (P<0.05). Multivariate Cox regression analysis revealed that the miR-148b level (P=0.003) was an independent prognostic factor affecting the prognosis. The results of this study showed that the expression of miR-148b in stage-I and II parosteal osteosarcoma tissues declines, which is related to the poor clinical prognosis of parosteal osteosarcoma.

View Figures

View References

1	Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
2	Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
3	Azizi M, Teimoori-Toolabi L, Arzanani MK, Azadmanesh K, Fard-Esfahani P and Zeinali S: MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. Cancer Biol Ther. 15:419–427. 2014. View Article : Google Scholar : PubMed/NCBI
4	Zhang JG, Shi Y, Hong DF, Song M, Huang D, Wang CY and Zhao G: MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/β-catenin pathway. Sci Rep. 5:80872015. View Article : Google Scholar : PubMed/NCBI
5	Borel F, Konstantinova P and Jansen PL: Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol. 56:1371–1383. 2012. View Article : Google Scholar : PubMed/NCBI
6	Liu Q, Xu Y, Wei S, Gao W, Chen L, Zhou T, Wang Z, Ying M and Zheng Q: miRNA-148b suppresses hepatic cancer stem cell by targeting neuropilin-1. Biosci Rep. 35:e002292015. View Article : Google Scholar : PubMed/NCBI
7	Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu RX, Liu SH, Yi QT, Li J and Song CH: Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol. 36:3035–3042. 2015. View Article : Google Scholar : PubMed/NCBI
8	Li T, Yin J, Yuan L, Wang S, Yang L, Du X and Lu J: Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival. Oncol Rep. 31:1699–1706. 2014. View Article : Google Scholar : PubMed/NCBI
9	Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, et al: St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project: Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 7:104–112. 2014. View Article : Google Scholar : PubMed/NCBI
10	Cheng D, Qiu X, Zhuang M, Zhu C, Zou H and Liu Z: MicroRNAs with prognostic significance in osteosarcoma: A systemic review and meta-analysis. Oncotarget. 8:81062–81074. 2017. View Article : Google Scholar : PubMed/NCBI
11	Wang Z and Cai H, Lin L, Tang M and Cai H: Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. Pediatr Blood Cancer. 61:206–210. 2014. View Article : Google Scholar : PubMed/NCBI
12	Wu X, Zhong D, Gao Q, Zhai W, Ding Z and Wu J: MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether à go-go 1 expression. Int J Med Sci. 10:676–682. 2013. View Article : Google Scholar : PubMed/NCBI
13	Cote GA, Gore AJ, McElyea SD, Heathers LE, Xu H, Sherman S and Korc M: A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile. Am J Gastroenterol. 109:1942–1952. 2014. View Article : Google Scholar : PubMed/NCBI
14	Dahlmans D, Houzelle A, Schrauwen P and Hoeks J: Mitochondrial dynamics, quality control and miRNA regulation in skeletal muscle: Implications for obesity and related metabolic disease. Clin Sci (Lond). 130:843–852. 2016. View Article : Google Scholar : PubMed/NCBI
15	Wu M, Ye X, Wang S, Li Q, Lai Y and Yi Y: MicroRNA-148b suppresses proliferation, migration, and invasion of nasopharyngeal carcinoma cells by targeting metastasis-associated gene 2. OncoTargets Ther. 10:2815–2822. 2017. View Article : Google Scholar
16	Drakaki A, Hatziapostolou M, Polytarchou C, Vorvis C, Poultsides GA, Souglakos J, Georgoulias V and Iliopoulos D: Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. BMC Cancer. 15:5422015. View Article : Google Scholar : PubMed/NCBI
17	Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu RX, Liu SH, Yi QT, Li J and Song CH: Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol. 36:3035–3042. 2015. View Article : Google Scholar : PubMed/NCBI
18	Ge H, Li B, Hu WX, Li RJ, Jin H, Gao MM and Ding CM: MicroRNA-148b is down-regulated in non-small cell lung cancer and associated with poor survival. Int J Clin Exp Pathol. 8:800–805. 2015.PubMed/NCBI
19	Josefsson A, Hobbs R, Mauxion T, Frey E, Terezakis S, Meyer C, Loeb D and Sgouros G: Combined treatment planning and therapy using 153Sm-EDTMP RPT with XRT in pediatric metastatic osteosarcoma patients. J Nucl Med. 56:3412015.
20	Xu YF, Jiang SJ, Wang YQ, Yao YW and Liu YX: A survival analysis and treatment outcomes of 131 cases of osteosarcoma treated with high-dose methotrexate multidrug chemotherapy. Int J Clin Exp Med. 9:8465–8473. 2016.